muvalaplin

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • 100-800 mg daily

Adverse effects

  • not associated with tolerability concerns

Mechanism of action

  • selective small molecule inhibitor of Lp(a) formation
    • lowers Lp(a) levels as much as 65% after daily administration for 14 days

More general terms

References

  1. Nicholls SJ, Nissen SE, Fleming C et al Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation. A Randomized Clinical Trial. JAMA. Published online August 28, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37638695 https://jamanetwork.com/journals/jama/fullarticle/2808864